TUCSON, Ariz.--(BUSINESS WIRE)--SynCardia Systems, Inc., manufacturer of the world’s first and only FDA and CE Mark approved temporary Total Artificial Heart, is looking to the future so this lifesaving technology can be used to save more patients. To reach this goal the company has researched and recruited five of the world’s leading biomedical scientists and physicians to review the CardioWest™ temporary Total Artificial Heart (TAH-t). The Science Advisory Board (SAB) met on March 15th and 16th in Tucson, Arizona.
